GLPwatch
Xultophy for Smoking cessation
liraglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCXultophy (liraglutide) is not FDA-approved for smoking cessation, and any use for this condition is off-label or investigational. Research in rats suggests liraglutide may reduce nicotine self-administration and withdrawal symptoms, but no human studies on smoking cessation were listed.
AI summary of the sources below.
| Drug | Xultophy (liraglutide) |
|---|---|
| Condition | Smoking cessation |
| Approval status | Investigational / off-label |
| Research papers | 3 |
Xultophy is not FDA-approved for smoking cessation; the research below reflects investigational or off-label study only.
Research on liraglutide for smoking cessation (3)
- Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats.
- Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial.
- Smoke or fire? Acute pancreatitis and the liraglutide trials.